The annual incidence of aneurysmal subarachnoid hemorrhage (SAH) adjusted for age and sex, is 7.8-23.0 per 100,000 population. In a systematic review, mortality after aneurysmal SAH is reported between 32 and 67%, mainly caused by rebleeding and delayed cerebral ischemia. Consequently, treatment is aimed at the prevention of a rebleed by the obliteration of the aneurysm and the prevention and treatment of delayed cerebral ischemia. Deleterious effect of low blood pressure and antihypertensive agents after SAH has been reported. A vast number of articles has been published on the outcome of patients after aneurysmal SAH, disregarding the influence of cardiac dysfunction, although it is known for many years that cardiac abnormalities, defined as echocardiographic wall motion abnormalities (WMA), electrocardiographic (ECG) changes and elevated biochemical markers of myocardial damage, may occur during SAH.
The S.E.A.S. study is a prospective multi-center, multidisciplinary observational study
The S.E.A.S. study aims at:
Identifying the frequency of myocardial dysfunction in patients with SAH
Determination of predictive clinical variables for the occurrence of myocardial dysfunction following SAH.
Assessment of the impact of cardiac dysfunction on outcome at 3 months on the Glasgow Outcome Scale.
The S.E.A.S. study will include 400 patients over a period of two-three years
The S.E.A.S. study is registered with Clinical Trials.gov
Substudies are S.M.A.S.H., S.Q.U.A.S.H., and F.RE.S.H.